Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, founded in 1994 and headquartered in New York City, operates as a clinical-stage biopharmaceutical company. David P. Luci has served as President and CEO since at least 2016, steering the company toward a narrow but urgent therapeutic focus: infections caused by Gram-positive bacteria, particularly Clostridioides difficile. The company’s strategy centers on the development of its lead product candidate, ibezapolstat, an oral antibiotic for C. difficile infection. Acurx is also researching polymerase inhibitors for other Gram-positive bacteria. The firm funds operations through public equity markets — its shares trade on Nasdaq under the ticker ACXP. It has not disclosed a dedicated asset manager or family office structure, nor any external fund commitments. As of mid-2024, Acurx had reported positive Phase 2a clinical data for ibezapolstat in C. difficile patients and was preparing for Phase 2b/3 trials. The company has no disclosed AUM, deployment figures, or team size beyond its named executive officers. It maintains a single office in New York and has not listed additional locations. Acurx's structural differentiator is its focus on novel antibiotics for Gram-positive infections, an area where few new drugs have entered the market in decades. The company does not operate under a family office model; it is a publicly traded biotech firm. Its ongoing clinical trials and reliance on equity financing define its capital posture.